Clinical Trials Browser

Neuroblastoma × Sorafenib × Clear all

NCT02559778 2026-02-20

PEDS-PLAN

Phase 2 Recruiting

Neuroblastoma

NCT02298348 2025-02-17

N2013-02

Phase 1 Active not recruiting

Neuroblastoma, Recurrence

NCT01518413 2015-02-27

Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors

Phase 1 Completed

Brain Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma